Proteasome inhibitors impair RANKL-Induced NF-κB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IκBα signaling cascades

Journal of Cellular Physiology

Volumn 220, Issue 2, 2009, Pages 450-459

  Ang, Estabelle ^a   Pavlos, Nathan J ^a   Rea, Sarah L ^b,c   Qi, Ming ^a   Chai, Tracy ^a   Walsh, John P ^b   Ratajczak, Thomas ^b,c   Zheng, Ming H ^a   Xu, Jiake ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; EPOXOMICIN; F ACTIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME INHIBITOR; PROTEIN P62; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; ACTIN; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CARBOBENZOXY LEUCYL LEUCYL NORVALINAL; CARBOBENZOXY-LEUCYL-LEUCYL-NORVALINAL; CYLD PROTEIN, MOUSE; CYSTEINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; ERYTHROPOIETIN; GTF2H1 PROTEIN, MOUSE; I KAPPA B; LEUPEPTIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; OLIGOPEPTIDE; PROTEASOME; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYLINDROMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROTUBULE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; ANIMAL; C57BL MOUSE; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ACTINS; ANIMALS; BONE RESORPTION; CELL LINE; CYSTEINE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; ERYTHROPOIETIN; HUMANS; I-KAPPA B PROTEINS; LEUPEPTINS; MICE; MICE, INBRED C57BL; MICROTUBULES; NF-KAPPA B; OLIGOPEPTIDES; OSTEOCLASTS; PROTEASOME ENDOPEPTIDASE COMPLEX; RANK LIGAND; SIGNAL TRANSDUCTION; SYNAPTOTAGMIN I; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSCRIPTION FACTORS;

EID: 67649366019     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21787     Document Type: Article

References (44)

1. Ahn KS, Sethi G, Chao TH, Neuteboom ST, Chaturvedi MM, Palladino MA, Younes A, Aggarwal BB. 2007. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 110:2286-2295.
2. Almond JB, Cohen GM. 2002. The proteasome: A novel target for cancer chemotherapy. Leukemia 16:433-443.
3. Berenson JR. 2002. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 29:11-16.
4. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
5. Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC. 2004. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279:54841-54848.
6. ChauhanD,Hideshima T, Anderson KC. 2006. A novel proteasome inhibitorNPI-0052 as an anticancer therapy. Br J Cancer 95:961-965.
7. Ciechanover A. 2005. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 12:1178-1190.
8. Ciechanover A, Schwartz AL. 1998. The ubiquitin-proteasome pathway: The complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95:2727-2730.
9. Dai S, Hirayama T, Abbas S, Abu-Amer Y. 2004. The IkappaB kinase (IKK) inhibitor, NEMObinding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279:37219-37222.
10. Dixit V, Mak TW. 2002. NF-kappaB signaling. Many roads lead to madrid. Cell 111:615-619.
11. Duran A, SerranoM, Leitges M, Flores JM, Picard S, Brown JP, Moscat J,Diaz-Meco MT. 2004. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303-309.
12. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496.
13. Garrett IR, Chen D, Gutierrez G, ZhaoM, EscobedoA, RossiniG,Harris SE,Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771-1782.
14. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem 67:425-479.
15. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
16. Huang L, Xu J, Wood DJ, Zheng MH. 2000. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator ofNF-kappaB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156:761-767.
17. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3:1285-1289.
18. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T. 1999. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163:434-442.
19. Jin W, Chang M, Paul EM, Babu G, Lee AJ, ReileyW,Wright A, Zhang M, You J, Sun SC. 2008. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 118:1858-1866.
20. Kim HH, Lee DE, Shin JN, Lee YS, Jeon YM, Chung CH, Ni J, Kwon BS, Lee ZH. 1999. Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443:297-302.
21. Kisselev AF, Goldberg AL. 2001. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8:739-758.
22. Kuusisto E, Suuronen T, Salminen A. 2001. Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells. Biochem Biophys Res Commun 280:223-228.
23. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
24. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015-1024.
25. Mackenzie GG, Keen CL, Oteiza PI. 2006. Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: Modulation by zinc. J Neurochem 99:402-415.
26. Mercurio F, Manning AM. 1999. Multiple signals converging on NF-kappaB. Curr Opin Cell Biol 11:226-232.
27. Pavlos NJ, Xu J, Riedel D, Yeoh JS, Teitelbaum SL, Papadimitriou JM, Jahn R, Ross FP, Zheng MH. 2005. Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 25:5253-5269.
28. Pickart CM. 2004. Back to the future with ubiquitin. Cell 116:181-190.
29. Rea SL, Walsh JP, Ward L, Yip K, Ward BK, Kent GN, Steer JH, Xu J, Ratajczak T. 2006. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NFkappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 21:1136-1145.
30. Richardson PG. 2004.Areview of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5:1321-1331.
31. Tahmatzopoulos A, Gudegast C, Stockle M, Wullich B, UntereggerG, ZwergelU, Zwergel T. 2004. Proteasome inhibitors: Induction of apoptosis as new therapeutic option in prostate cancer. Aktuelle Urol 35:491-496.
32. Teitelbaum SL. 2007. Osteoclasts: What do they do and how do they do it? Am J Pathol 170:427-435.
33. vonMetzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, MiethM, KaiserM, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O. 2007. Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025-2034.
34. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. 2003. The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325.
35. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J. 2003. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res 18:2159-2168.
36. Whiteside ST, Israel A. 1997. I kappa B proteins: Structure, function and regulation. Semin Cancer Biol 8:75-82.
37. Winslow MM, Pan M, Starbuck M, Gallo EM, Deng L, Karsenty G, Crabtree GR. 2006. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 10:771-782.
38. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186:2075-2080.
39. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH. 2000. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 15:2178-2186.
40. Xu J, Feng HT, Wang C, Yip KH, Pavlos N, Papadimitriou JM, Wood D, Zheng MH. 2003. Effects of bafilomycin. A1: An inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts. J Cell Biochem 88:1256-1264.
41. Xu J, Wu H, Ang E, Yip KH, Woloszyn M, Zheng MH, Tan R. 2009. NF-kB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 20:7-17.
42. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J. 2004. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 19:1905-1916.
43. Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J. 2006. p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: A new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169:503-514.
44. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O. 2005. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333:200-205.